Advertisement
Screener

GILEAD SCIENCES, INC. (GILD) Other Comprehensive Income (Loss), Reclassification Adjustment on Derivatives Included in Net Income, Tax (Deprecated 2013-01-31)

1.8 / 5 stars · 42/120 Roast Me

GILEAD SCIENCES, INC. Other Comprehensive Income (Loss), Reclassification Adjustment on Derivatives Included in Net Income, Tax (Deprecated 2013-01-31)

GILEAD SCIENCES, INC. (GILD) reported Other Comprehensive Income (Loss), Reclassification Adjustment on Derivatives Included in Net Income, Tax (Deprecated 2013-01-31) of -$11.00 thousand for the 3-month period ending 2013-03-31, per its 10-Q filed 2013-05-08.

Discontinued › Expense Statement › Income Tax

us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentOnDerivativesIncludedInNetIncomeTax · last filed 2013-05-08

  • GILEAD SCIENCES, INC. other comprehensive income (loss), reclassification adjustment on derivatives included in net income, tax (deprecated 2013-01-31) for the quarter ending 2013-03-31 was -$11.00K.
  • GILEAD SCIENCES, INC. other comprehensive income (loss), reclassification adjustment on derivatives included in net income, tax (deprecated 2013-01-31) for the quarter ending 2012-12-31 was $985.00K, a 43.19% decline year-over-year.
  • GILEAD SCIENCES, INC. other comprehensive income (loss), reclassification adjustment on derivatives included in net income, tax (deprecated 2013-01-31) for the quarter ending 2012-09-30 was -$1.76M, a 188.98% decline year-over-year.
  • GILEAD SCIENCES, INC. other comprehensive income (loss), reclassification adjustment on derivatives included in net income, tax (deprecated 2013-01-31) for the quarter ending 2012-06-30 was -$548.00K, a 149.59% decline year-over-year.
  • GILEAD SCIENCES, INC. other comprehensive income (loss), reclassification adjustment on derivatives included in net income, tax (deprecated 2013-01-31) for fiscal 2012 was -$2.17M, a 149.46% decline from fiscal 2011.
  • GILEAD SCIENCES, INC. other comprehensive income (loss), reclassification adjustment on derivatives included in net income, tax (deprecated 2013-01-31) for fiscal 2011 was $4.39M.
  • GILEAD SCIENCES, INC. other comprehensive income (loss), reclassification adjustment on derivatives included in net income, tax (deprecated 2013-01-31) for fiscal 2010 was -$5.86M.
Period endOther Comprehensive Income (Loss), Reclassification Adjustment on Derivatives Included in Net Income, Tax (Deprecated 2013-01-31) 3 monthOther Comprehensive Income (Loss), Reclassification Adjustment on Derivatives Included in Net Income, Tax (Deprecated 2013-01-31) 6 monthOther Comprehensive Income (Loss), Reclassification Adjustment on Derivatives Included in Net Income, Tax (Deprecated 2013-01-31) 9 monthOther Comprehensive Income (Loss), Reclassification Adjustment on Derivatives Included in Net Income, Tax (Deprecated 2013-01-31) 12 month
2013-03-31-$11.00K
10-Q · filed 2013-05-08
$974.00K
derived: sum of 2 quarters · filed 2013-05-08
-$786.00K
derived: sum of 3 quarters · filed 2013-05-08
-$1.33M
derived: sum of 4 quarters · filed 2013-05-08
2012-12-31$985.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-27
-$775.00K
derived: sum of 2 quarters · filed 2013-02-27
-$1.32M
derived: sum of 3 quarters · filed 2013-02-27
-$2.17M
10-K · filed 2013-02-27
2012-09-30-$1.76M
10-Q · filed 2012-11-06
-$2.31M
derived: sum of 2 quarters · filed 2012-11-06
-$3.16M
10-Q · filed 2012-11-06
-$974.00K
derived: sum of 4 quarters · filed 2013-05-08
2012-06-30-$548.00K
10-Q · filed 2012-08-01
-$994.00K
10-Q · filed 2012-08-01
$786.00K
derived: sum of 3 quarters · filed 2013-05-08
$2.76M
derived: sum of 4 quarters · filed 2013-05-08
2012-03-31-$400.00K
10-Q · filed 2013-05-08
$1.33M
derived: sum of 2 quarters · filed 2013-05-08
$3.31M
derived: sum of 3 quarters · filed 2013-05-08
$4.42M
derived: sum of 4 quarters · filed 2013-05-08
2011-12-31$1.73M
derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-27
$3.71M
derived: sum of 2 quarters · filed 2013-02-27
$4.82M
derived: sum of 3 quarters · filed 2013-02-27
$4.39M
10-K · filed 2013-02-27
2011-09-30$1.98M
10-Q · filed 2012-11-06
$3.08M
derived: sum of 2 quarters · filed 2012-11-06
$2.65M
10-Q · filed 2012-11-06
2011-06-30$1.10M
10-Q · filed 2012-08-01
$6.00K
10-Q · filed 2012-08-01
2010-12-31-$5.86M
10-K · filed 2013-02-27

Similar stocks

Stock NameCountryMarket CapPE Ratio
AMGEN INC (AMGN)United States$219.567B22.39
Moderna, Inc. (MRNA)United States$77.819B-8.86
Revolution Medicines, Inc. (RVMD)United States$42.805B-22.69
BIOGEN INC. (BIIB)United States$33.427B19.60
EXELIXIS, INC. (EXEL)United States$14.358B16.15
NEUROCRINE BIOSCIENCES INC (NBIX)United States$14.131B24.25
HALOZYME THERAPEUTICS, INC. (HALO)United States$13.083B21.59
Twist Bioscience Corp (TWST)United States$11.540B-47.21
BIO-TECHNE Corp (TECH)United States$11.379B74.68
REPLIGEN CORP (RGEN)United States$10.755B185.31